Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
AMAG Pharmaceuticals is a biotechnology business based in the US. AMAG Pharmaceuticals shares (AMAG) are listed on the NASDAQ and all prices are listed in US Dollars. AMAG Pharmaceuticals employs 440 staff and has a trailing 12-month revenue of around $300.1 million.
| 52-week range | $0.00 - $0.00 |
|---|---|
| 50-day moving average | $13.72 |
| 200-day moving average | $10.32 |
| Wall St. target price | $11.96 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-6.83 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing AMAG Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AMAG Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
AMAG Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.32. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into AMAG Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
| Revenue TTM | $300.1 million |
|---|---|
| Gross profit TTM | $219.4 million |
| Return on assets TTM | -3.06% |
| Return on equity TTM | 0% |
| Profit margin | -77.18% |
| Book value | $7.42 |
| Market Capitalization | $477.5 million |
TTM: trailing 12 months
We're not expecting AMAG Pharmaceuticals to pay a dividend over the next 12 months.
AMAG Pharmaceuticals's shares were split on a 3:2 basis on 25 September 1991. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your AMAG Pharmaceuticals shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for AMAG Pharmaceuticals shares which in turn could have impacted AMAG Pharmaceuticals's share price.
Over the last 12 months, AMAG Pharmaceuticals's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AMAG Pharmaceuticals's is 0.8675. This would suggest that AMAG Pharmaceuticals's shares are less volatile than average (for this exchange).
AMAG Pharmaceuticals, Inc. , a pharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, and anemia management in the United States. The company markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and Vyleesi (bremelanotide), an auto-injector device for the treatment of hypoactive sexual desire disorder in pre-menopausal women. Its product candidates also include AMAG-423 (ovine), an antibody fragment, which is in Phase 2b/3a trial for the treatment of severe preeclampsia in pregnant women; and Ciraparantag, an anticoagulant reversal agent that is in planned Phase 2b trial for the treatment of novel oral anticoagulants or low molecular weight heparin. The company sells Feraheme to authorized wholesalers and specialty distributors. The company has license agreements with Endoceutics, Inc. , Palatin Technologies, Inc.
Learn the basics of call options: what they are, how they work and examples.
These are the 10 best stocks to buy right now, trading on the Nasdaq and NYSE.
Features and fees to consider before you open an account with this trading platform.
Compare pros, cons, research tools and reviews for these two trading platforms.
What you need to know about investing in the leading indicator for the overall US stock market.
There are many ways to invest and grow $50K depending on your financial situation, personal needs and goals.
Take advantage of commission-free trading with stocks, ETFs and options with a flexible trading platform.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
Check out the best-performing ETFs so far in 2024.